# PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors

> **NCT07510828** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beijing Biotech** · enrollment: 60 (estimated)

## Conditions studied

- Advanced or Metastatic Solid Tumors

## Interventions

- **BIOLOGICAL:** EB-PT-CAR-NK-S
- **BIOLOGICAL:** EB-PT-CAR-NK-D
- **DRUG:** Lymphodepleting chemotherapy
- **DRUG:** Cytokine support

## Key facts

- **NCT ID:** NCT07510828
- **Lead sponsor:** Beijing Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-02
- **Primary completion:** 2027-03-14
- **Final completion:** 2028-04-17
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07510828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07510828, "PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07510828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*